Literature DB >> 15084684

Loss of seizure control due to anticonvulsant-induced hypocalcemia.

Fawzi Elhami Ali1, Mahmoud A Al-Bustan, Waleed A Al-Busairi, Fatema A Al-Mulla.   

Abstract

OBJECTIVE: To report a case of loss of seizure control due to hypocalcemia resulting from long-term treatment with phenytoin and phenobarbital. CASE
SUMMARY: A 32-year-old mentally retarded man presented with a 12-month history of loss of seizure control, after being seizure-free for 5 years on a fixed regimen of phenobarbital and phenytoin. He had been institutionalized at the age of 10 years and had received anticonvulsant drugs since he was diagnosed with tonic-clonic epilepsy 20 years ago. On investigation, serum concentrations of the anticonvulsant drugs were within the therapeutic range, indicating adequate medication dosages. Serum biochemistry was consistent with vitamin D deficiency: hypocalcemia, reduced 25-hydroxyvitamin D, increased alkaline phosphatase, and increased parathormone. Seizure control was regained after serum calcium had been normalized with administration of vitamin D and calcium. DISCUSSION: Antiepileptic drugs (AEDs) cause vitamin D deficiency through induction of hepatic microsomal enzymes that metabolize vitamin D. Institutionalized subjects are more vulnerable because of the added factors of multidrug therapy, poor diet, reduced exposure to sunlight, and physical inactivity. The resulting hypocalcemia can cause reactive seizures, thus offsetting the anticonvulsant action of the drugs. An objective causality assessment revealed that the adverse reactions of both phenobarbital and phenytoin were probable.
CONCLUSIONS: Hypocalcemic seizures are uncommon and underdiagnosed complications of long-term therapy with AEDs. Loss of seizure control in a patient stabilized on AEDs is an indication to check the patient's calcium status. Proper treatment of this complication is vitamin D and calcium supplementation. Prophylactic supplementation with vitamin D is necessary in institutionalized patients treated with AEDs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15084684     DOI: 10.1345/aph.1D467

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  8 in total

1.  Clinical and laboratory features of patients with osteomalacia initially presenting with neurological manifestations.

Authors:  S W Kim; N Hong; Y Rhee; Y-C Choi; H Y Shin; S M Kim
Journal:  Osteoporos Int       Date:  2018-04-05       Impact factor: 4.507

Review 2.  Drug-Nutrition Interactions and the Brain: It's Not All in Your Head.

Authors:  Joseph I Boullata
Journal:  Curr Nutr Rep       Date:  2019-06

3.  Partial response to cinacalcet treatment in a patient with secondary hyperparathyroidism undergoing hemodialysis: a case report.

Authors:  Giovanni Conzo; Alessandra F Perna; Salvatore Napolitano; Claudio Mauriello; Claudio Gambardella; Ersilia Satta; Giuseppe Ciancia; Giovanbattista Capasso; Luigi Santini
Journal:  J Med Case Rep       Date:  2012-12-11

4.  An interictal schizophrenia-like psychosis in an adult patient with 22q11.2 deletion syndrome.

Authors:  Yasutaka Tastuzawa; Kanako Sekikawa; Tetsufumi Suda; Hiroshi Matsumoto; Hiroyuki Otabe; Shigeaki Nonoyama; Aihide Yoshino
Journal:  Epilepsy Behav Case Rep       Date:  2015-04-06

Review 5.  Hypocalcemia-induced seizure: demystifying the calcium paradox.

Authors:  Pengcheng Han; Bradley J Trinidad; Jiong Shi
Journal:  ASN Neuro       Date:  2015-03-24       Impact factor: 4.146

6.  Do current screening recommendations allow for early detection of lithium-induced hyperparathyroidism in patients with bipolar disorder?

Authors:  Michael Berger; Michael Riedel; Nora Tomova; Michael Obermeier; Florian Seemüller; Sandra Dittmann; Hans-Jürgen Moeller; Emanuel Severus
Journal:  Int J Bipolar Disord       Date:  2013-06-14

Review 7.  Vitamin D3 for the Treatment of Epilepsy: Basic Mechanisms, Animal Models, and Clinical Trials.

Authors:  Kevin Pendo; Christopher M DeGiorgio
Journal:  Front Neurol       Date:  2016-12-08       Impact factor: 4.003

8.  Pseudohypoparathyroidism type Ia manifesting as intractable epilepsy in a 23-year-old female.

Authors:  Pooja Raghavan; Charles M Katz
Journal:  Int Med Case Rep J       Date:  2012-07-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.